Cargando…
Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic
Autores principales: | Katsiki, Niki, Banach, Maciej, Mikhailidis, Dimitri P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212217/ https://www.ncbi.nlm.nih.gov/pubmed/32399093 http://dx.doi.org/10.5114/aoms.2020.94503 |
Ejemplares similares
-
Renin-angiotensin system inhibition in COVID-19 patients
por: de Vries, A. A. F.
Publicado: (2020) -
More Good News on Statins and COVID-19
por: Katsiki, Niki, et al.
Publicado: (2021) -
Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!
por: Katsiki, Niki, et al.
Publicado: (2019) -
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020) -
Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19
por: Sarzani, Riccardo, et al.
Publicado: (2020)